TRANSCODE THERAPEUTICS, INC.
  • Home
    • Mission
    • Clinical Trials
  • About
    • Metastatic Disease
    • Lead Candidate
    • Science
    • Pipeline >
      • Delivery Platform
      • Other Products
    • Leadership
  • Publications
  • Investors
  • Careers
    • Partnering

TTX-MC138

Lead Candidate: TTX-MC138

Small, non-coding strands of RNA have been identified as a significant player in the pathology of cancer. One of the first miRNAs to be shown as having aberrant expression in cancer was miR-10b. Since the inaugural study on miR-10b, its role as a metastasis promoting factor has been extensively validated, as a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon, glioblastomas, and others. To date, more than 100 studies have been completed on miR-10b and metastasis across 18 cancer types.

​TransCode’s lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b (miR-10b) and eliminate metastasis. We believe that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. ​
Picture
Picture

​Pre-Clinical Evidence

In multiple pre-clinical models of triple-negative breast cancer (TNBC), treatment with low-dose chemotherapy and TTX-MC138 eliminated pre-existing local metastases in 100% of treated animals representative of stage II/III metastatic cancer.

In models representative of stage IV metastatic cancer, treatment with low-dose chemotherapy and TTX-MC138 resulted in elimination of distant metastases in 65% of animals treated.
Picture
Picture
Sources: Yoo B, et al. Cancer Res. 2015;75(20):4407-4415; Yoo B, et al. Sci Rep. 2017;7:45060; Figure 11 in S-1 Preclinical results of TTX-MC138 in models of metastatic breast cancer.

Notably, no recurrence of metastases occurred following TTX-MC138 treatment cessation. ​

Clinical Path Forward

A first in human Phase O study with TTX-MC138 is planned for 2H of 2022, and is expected to be followed by Phase I/II in 2023.

Other Candidates

Learn more about TransCode's other therapeutic candidates.
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.

Home

​MISSION
​CLINICAL TRIALS

About

​METASTATIC DISEASE
TTX-MC138
​SCIENCE
​PIPELINE
​DELIVERY PLATFORM
​OTHER PRODUCTS
​LEADERSHIP


Publications

​PUBLICATIONS

Careers

​​​​​CAREERS
​
PARTNERING




Contact/Support

CONTACT
​TERMS OF USE
PRIVACY POLICY
FCOI Policy
​
© TRANSCODE THERAPEUTICS, INC. 2023.​ ALL RIGHTS RESERVED.
  • Home
    • Mission
    • Clinical Trials
  • About
    • Metastatic Disease
    • Lead Candidate
    • Science
    • Pipeline >
      • Delivery Platform
      • Other Products
    • Leadership
  • Publications
  • Investors
  • Careers
    • Partnering